UPM-KYMMENE OYJ financials
UPM-KYMMENE OYJ
Country: FI Reporting currency: EUR Latest annual report: 2025-12-31
LEI:
213800EC6PW5VU4J9U64 Financial statements
(EUR, as reported — unscaled; 124 line items across 2 annual periods)
| Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Other income | €174.0M | €130.0M |
| Operating profit (EBIT) | €749.0M | €604.0M |
| Net finance income / (cost) | -€102.0M | -€97.0M |
| Profit before tax | €690.0M | €500.0M |
| Income tax expense | €200.0M | €37.0M |
| Profit for the year | €491.0M | €463.0M |
| — attributable to owners | €480.0M | €436.0M |
| — attributable to NCI | €11.0M | €27.0M |
| Total comprehensive income | -€214.0M | €831.0M |
| Per share | ||
| Basic EPS | €0.91 | €0.82 |
| Diluted EPS | €0.91 | €0.82 |
| Free cash flow / share | €1.93 | €1.43 |
| Cash flow statement | ||
| Net cash from operating activities | €1.41B | €1.35B |
| Income taxes paid | €96.0M | €144.0M |
| Net cash from investing activities | -€428.0M | -€586.0M |
| Net cash from financing activities | -€1.14B | -€544.0M |
| Dividends paid | -€816.0M | -€819.0M |
| Lease liability payments | €112.0M | €105.0M |
| Balance sheet | ||
| Total assets | €17.53B | €19.10B |
| Non-current assets | €13.34B | €14.06B |
| Property, plant & equipment | €6.46B | €7.08B |
| Right-of-use assets | €778.0M | €847.0M |
| Intangible assets & goodwill | €264.0M | €174.0M |
| Inventories | €1.89B | €2.10B |
| Trade & other receivables | €1.48B | €1.93B |
| Cash & equivalents | €715.0M | €892.0M |
| Total equity | €10.34B | €11.54B |
| — attributable to owners | €10.00B | €11.14B |
| Non-controlling interests | €333.0M | €401.0M |
| Non-current liabilities | €4.96B | €5.16B |
| Long-term borrowings | €3.64B | €3.75B |
| Trade & other payables | €1.84B | €1.94B |
| Deferred tax liabilities | €692.0M | €673.0M |
| Derived metrics | ||
| Free cash flow | €1.04B | €809.0M |
| Operating margin | 7.8% | 5.8% |
| Net margin | 5.1% | 4.5% |
| Return on equity | 4.8% | 4.0% |
| Cash conversion ratio | 2.86× | 2.92× |
| Capex coverage | 3.86× | 2.49× |
| Other reported items | ||
| Adjustments For Decrease Increase In Biological Assets | -€144.0M | -€80.0M |
| Adjustments For Decrease Increase In Trade and Other Receivables | €396.0M | -€81.0M |
| Adjustments For Depreciation and Amortisation Expense | €594.0M | €1.14B |
| Adjustments For Finance Income Cost | -€59.0M | -€104.0M |
| Adjustments For Income Tax Expense | €200.0M | €37.0M |
| Adjustments For Increase Decrease In Trade and Other Payables | -€128.0M | €95.0M |
| Adjustments For Losses Gains On Disposal of Noncurrent Assets | -€57.0M | -€31.0M |
| Adjustments For Provisions | €125.0M | €101.0M |
| Adjustments For Reconcile Profit Loss | €743.0M | €1.22B |
| Adjustments For Undistributed Profits of Investments Accounted For Using Equity Method | €0 | €1.0M |
| Cancellation of Treasury Shares | €0 | — |
| Cash and Cash Equivalents Classified As Part of Disposal Group Held For Sale | €0 | -€39.0M |
| Cash Flows From Losing Control of Subsidiaries Or Other Businesses Classified As Investing Activities | €0 | €16.0M |
| Cash Flows From Used In Increase Decrease In Current Borrowings | €32.0M | -€182.0M |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | €124.0M | €28.0M |
| Cash Receipts From Future Contracts Forward Contracts Option Contracts and Swap Contracts Classified As Investing Activities | €20.0M | -€1.0M |
| Changes In Inventories of Finished Goods and Work In Progress | €123.0M | -€94.0M |
| Comprehensive Income Attributable To Noncontrolling Interests | -€34.0M | €50.0M |
| Comprehensive Income Attributable To Owners of Parent | -€180.0M | €781.0M |
| Current Assets Other Than Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners | €4.19B | €5.03B |
| Current Borrowings and Current Portion of Noncurrent Borrowings | €156.0M | €166.0M |
| Current Liabilities Other Than Liabilities Included In Disposal Groups Classified As Held For Sale | €2.24B | €2.40B |
| Current Provisions | €179.0M | €165.0M |
| Current Tax Assets Current | €35.0M | €40.0M |
| Current Tax Liabilities Current | €25.0M | €18.0M |
| Deferred Tax Assets | €413.0M | €526.0M |
| Depreciation Amortisation and Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | €594.0M | €1.14B |
| Dividends Paid To Equity Holders of Parent Classified As Financing Activities | €792.0M | €801.0M |
| Dividends Paid To Noncontrolling Interests Classified As Financing Activities | €23.0M | €19.0M |
| Dividends Proposed Or Declared Before Financial Statements Authorised For Issue But Not Recognised As Distribution To Owners | €791.0M | — |
| Dividends Proposed Or Declared Before Financial Statements Authorised For Issue But Not Recognised As Distribution To Owners Per Share | €1.50 | — |
| Dividends Received Classified As Operating Activities | €8.0M | €4.0M |
| Dividends Recognised As Distributions To Owners Per Share | €1.50 | — |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -€19.0M | -€2.0M |
| Equity and Liabilities | €17.53B | €19.10B |
| Gains Losses On Cash Flow Hedges Net of Tax | €106.0M | €72.0M |
| Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss | €43.0M | -€7.0M |
| Income Taxes Paid Refund | €97.0M | €145.0M |
| Increase Decrease In Cash and Cash Equivalents | -€158.0M | €222.0M |
| Increase Decrease In Working Capital | -€391.0M | €80.0M |
| Increase Decrease Through Sharebased Payment Transactions | -€4.0M | -€2.0M |
| Increase Decrease Through Transactions With Owners | -€991.0M | -€822.0M |
| Increase Decrease Through Transfers and Other Changes Equity | -€1.0M | -€1.0M |
| Intangible Assets Other Than Goodwill | €554.0M | €580.0M |
| Interest Paid Classified As Operating Activities | €126.0M | €133.0M |
| Interest Received Classified As Operating Activities | €19.0M | €31.0M |
| Investment Accounted For Using Equity Method | €27.0M | €20.0M |
| Issued Capital | €890.0M | €890.0M |
| Liabilities | €7.20B | €7.56B |
| Noncurrent Biological Assets | €2.60B | €2.52B |
| Noncurrent Financial Assets At Fair Value Through Other Comprehensive Income | €2.19B | €2.25B |
| Noncurrent Provisions | €101.0M | €89.0M |
| Noncurrent Recognised Assets Defined Benefit Plan | €1.0M | €1.0M |
| Noncurrent Recognised Liabilities Defined Benefit Plan | €439.0M | €496.0M |
| Other Adjustments For Noncash Items | €60.0M | €74.0M |
| Other Comprehensive Income | -€705.0M | €368.0M |
| Other Comprehensive Income Net of Tax Cash Flow Hedges | €38.0M | €78.0M |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | -€724.0M | €346.0M |
| Other Comprehensive Income Net of Tax Financial Assets Measured At Fair Value Through Other Comprehensive Income | -€87.0M | -€47.0M |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | €31.0M | €4.0M |
| Other Comprehensive Income Net of Tax Hedges of Net Investments In Foreign Operations | €37.0M | -€13.0M |
| Other Current Financial Assets | €78.0M | €69.0M |
| Other Current Financial Liabilities | €37.0M | €108.0M |
| Other Inflows Outflows of Cash Classified As Financing Activities | -€1.0M | -€10.0M |
| Other Inflows Outflows of Cash Classified As Investing Activities | €0 | -€10.0M |
| Other Inflows Outflows of Cash Classified As Operating Activities | -€24.0M | -€13.0M |
| Other Noncurrent Assets | €22.0M | €21.0M |
| Other Noncurrent Financial Assets | €24.0M | €44.0M |
| Other Noncurrent Financial Liabilities | €90.0M | €158.0M |
| Other Reserves | €1.62B | €1.68B |
| Proceeds From Disposals of Property Plant and Equipment Intangible Assets Other Than Goodwill Investment Property and Other Noncurrent Assets | €84.0M | €10.0M |
| Proceeds From Noncurrent Borrowings | €65.0M | €600.0M |
| Proceeds From Sales of Biological Assets | €20.0M | €19.0M |
| Proceeds From Sales of Investments Accounted For Using Equity Method | €0 | €1.0M |
| Proceeds From Sales Or Maturity of Financial Instruments Classified As Investing Activities | €0 | €5.0M |
| Purchase of Biological Assets | €64.0M | €53.0M |
| Purchase of Property Plant and Equipment Intangible Assets Other Than Goodwill Investment Property and Other Noncurrent Assets | €364.0M | €543.0M |
| Purchase of Treasury Shares | -€160.0M | €0 |
| Reclassification Adjustments On Cash Flow Hedges For Which Hedged Item Affected Profit Or Loss Net of Tax | €68.0M | -€6.0M |
| Repayments of Noncurrent Borrowings | €148.0M | €23.0M |
| Reserve of Exchange Differences On Translation | €15.0M | €657.0M |
| Retained Earnings | €6.21B | €6.64B |
| Revenue From Contracts With Customers | €9.66B | €10.34B |
| Share of Profit Loss of Associates and Joint Ventures Accounted For Using Equity Method | €0 | €1.0M |
| Treasury Shares | €2.0M | €2.0M |
Methodology
Every line item above is a fact tagged in UPM-KYMMENE OYJ's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.